Larry Anderson, DO
Family Medicine · Dawsonville, GANPI 1932157856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $519 and has fallen 51.2% since, to $253 in 2025.
Across 99 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$236
- AstraZeneca$232
- Edwards Lifesciences$212
- Lilly USA, LLC$183
- Eisai Inc.$179
- GSK$174
- plus $993 from 19 others
Across 4 payments — averaging $192,826 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$771K
What the payments were for
- Food & beverage$2,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $236 |
| AstraZeneca | 7 | $232 |
| Edwards Lifesciences | 3 | $212 |
| Lilly USA, LLC | 10 | $183 |
| Eisai Inc. | 9 | $179 |
| GSK | 4 | $174 |
| Novo Nordisk | 9 | $146 |
| Boehringer Ingelheim | 5 | $131 |
| Amarin Pharma, Inc. | 5 | $91 |
| Pfizer | 5 | $87 |
| Grifols USA, LLC | 4 | $80 |
| Novartis | 4 | $70 |
| AbbVie | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $39 |
| Dexcom, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Astellas Pharma US Inc | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Exact Sciences | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$144
- FARXIGA$122
- TRELEGY ELLIPTA$121
How this compares
$2,210 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $144,859 |
| OzempicSemaglutide | 93 | $98,106 |
| MounjaroTirzepatide | 77 | $78,267 |
| JardianceEmpagliflozin | 19 | $41,671 |
| JanuviaSitagliptin Phosphate | 30 | $34,531 |
| FarxigaDapagliflozin Propanediol | 30 | $26,402 |
| EliquisApixaban | 22 | $23,699 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,373 |
| XareltoRivaroxaban | 17 | $13,554 |
| TrulicityDulaglutide | 11 | $10,565 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $9,144 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,988 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,575 |
| Risedronate Sodium | 30 | $3,899 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $80 | $144,85912 claims |
| Novo NordiskOzempic | $146 | $98,10693 claims |
| Lilly USA, LLCMounjaro, Trulicity | $183 | $88,83288 claims |
| MerckJanuvia, Janumet | $12 | $43,67644 claims |
| Boehringer IngelheimJardiance | $131 | $41,67119 claims |
| AstraZenecaFarxiga, Symbicort | $232 | $29,53442 claims |
| PfizerEliquis | $87 | $23,69922 claims |
| GSKTrelegy Ellipta, Shingrix | $174 | $18,90241 claims |
| AbbVieSynthroid | $53 | $2,10630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Dawsonville
- Ramzi GhosnDawsonville$17K
- Jeffrey KingsleyColumbus$404K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
- Elmore AlexanderStone Mountain$155K
- Bantwal BaligaColumbus$115K
- Avril CampbellFort Benning$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.